Table 1 Baseline characteristics and between-group analysis
Symbicort ® | Nebulized salbutamol | p value | |
|---|---|---|---|
Total no. of patients (n, %) | 15 | 17 | |
Mean age in years (SD) | 36.47 (16.26) | 42.59 (15.86) | |
Gender | |||
Male | 5 | 9 | |
Female | 10 | 8 | |
Objective parameters | |||
Mean PEFR improvement (SD) in l/min | Δ 78.67(44.86) | Δ 89.41(45.48) | 0.507 |
Median value (IQR) of improvement of SaO2 in % | Δ 1 (1) | Δ 2 (1) | 0.464 |
Median value (IQR) of reduction in respiratory rate (per min) | ∇ 2 (2)/min | ∇ (3)/min | 0.890 |
Subjective parameters | |||
5-point Likert scale: | - | - | |
1--much worse | - | - | |
2--a little worse | - | - | |
3--no change | - | - | |
4--a little better | 9 (60%) | 9 (52.9%) | |
5--much better | 6 (40%) | 8 (47.1%) | |
VAS changes in cm (SD) | 2.45 (1.31) | 2.20 (2.10) | 0.765 |